25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Aligos Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Aligos together

I guess you are interested in Aligos Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aligos Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aligos Therapeutics Inc

I send you an email if I find something interesting about Aligos Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Aligos (30 sec.)










1.2. What can you expect buying and holding a share of Aligos? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$7.99
Expected worth in 1 year
$14.71
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$6.73
Return On Investment
28.4%

For what price can you sell your share?

Current Price per Share
$23.67
Expected price per share
$6.76 - $34.53
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aligos (5 min.)




Live pricePrice per Share (EOD)
$23.67
Intrinsic Value Per Share
$-174.87 - $-207.58
Total Value Per Share
$-166.88 - $-199.60

2.2. Growth of Aligos (5 min.)




Is Aligos growing?

Current yearPrevious yearGrowGrow %
How rich?$50m$78.2m-$10.9m-16.3%

How much money is Aligos making?

Current yearPrevious yearGrowGrow %
Making money-$19.2m-$20.4m$1.1m6.1%
Net Profit Margin-1,404.2%-572.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Aligos (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#441 / 925

Most Revenue
#462 / 925

Most Profit
#649 / 925

Most Efficient
#727 / 925
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aligos?

Welcome investor! Aligos's management wants to use your money to grow the business. In return you get a share of Aligos.

First you should know what it really means to hold a share of Aligos. And how you can make/lose money.

Speculation

The Price per Share of Aligos is $23.67. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aligos.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aligos, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.99. Based on the TTM, the Book Value Change Per Share is $1.68 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aligos.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-3.07-13.0%-3.47-14.7%-0.47-2.0%-1.27-5.4%-1.27-5.4%
Usd Book Value Change Per Share-11.42-48.2%1.687.1%-0.40-1.7%0.401.7%0.401.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.070.3%0.070.3%
Usd Total Gains Per Share-11.42-48.2%1.687.1%-0.40-1.7%0.472.0%0.472.0%
Usd Price Per Share8.66-2.66-0.89-5.84-5.84-
Price to Earnings Ratio-0.71--0.19--0.47--1.66--1.66-
Price-to-Total Gains Ratio-0.76--0.10--2.26--3.01--3.01-
Price to Book Ratio1.08-0.31-0.51-1.16-1.16-
Price-to-Total Gains Ratio-0.76--0.10--2.26--3.01--3.01-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share23.67
Number of shares42
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.07
Usd Book Value Change Per Share1.680.40
Usd Total Gains Per Share1.680.47
Gains per Quarter (42 shares)70.6319.53
Gains per Year (42 shares)282.5178.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10283273116768
2056555622134146
3084883933201224
401130112244268302
501413140555335380
601695168866403458
701978197177470536
802260225488537614
902543253799604692
10028252820110671770

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%1.019.00.05.0%1.019.00.05.0%
Book Value Change Per Share3.01.00.075.0%3.09.00.025.0%6.013.01.030.0%6.013.01.030.0%6.013.01.030.0%
Dividend per Share0.00.04.00.0%1.00.011.08.3%2.00.018.010.0%2.00.018.010.0%2.00.018.010.0%
Total Gains per Share3.01.00.075.0%3.09.00.025.0%6.013.01.030.0%6.013.01.030.0%6.013.01.030.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aligos Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---11.4201.682-779%-0.398-97%0.399-2960%0.399-2960%
Book Value Per Share--7.98712.980-38%1.818+339%4.549+76%4.549+76%
Current Ratio--3.8095.047-25%3.678+4%5.719-33%5.719-33%
Debt To Asset Ratio--0.4330.437-1%0.325+33%0.515-16%0.515-16%
Debt To Equity Ratio--0.7650.799-4%0.485+58%0.468+64%0.468+64%
Dividend Per Share----0%0.003-100%0.066-100%0.066-100%
Enterprise Value--90910040.06068939023.719+32%99020932.403-8%356636021.035-75%356636021.035-75%
Eps---3.070-3.469+13%-0.474-85%-1.269-59%-1.269-59%
Ev To Ebitda Ratio---1.168-0.751-36%-1.185+1%-3.104+166%-3.104+166%
Ev To Sales Ratio--17.91012.651+42%6.838+162%68.765-74%68.765-74%
Free Cash Flow Per Share---3.209-4.303+34%-0.425-87%-1.346-58%-1.346-58%
Free Cash Flow To Equity Per Share---3.210-2.550-21%-0.422-87%-0.402-87%-0.402-87%
Gross Profit Margin--1.0000.977+2%1.0000%0.995+0%0.995+0%
Intrinsic Value_10Y_max---207.582--------
Intrinsic Value_10Y_min---174.870--------
Intrinsic Value_1Y_max---9.094--------
Intrinsic Value_1Y_min---8.925--------
Intrinsic Value_3Y_max---36.245--------
Intrinsic Value_3Y_min---34.423--------
Intrinsic Value_5Y_max---74.154--------
Intrinsic Value_5Y_min---68.060--------
Market Cap81997614.000+34%54318040.06016835023.719+223%38195182.403+42%202926966.828-73%202926966.828-73%
Net Profit Margin---15.177-14.042-7%-5.729-62%-14.503-4%-14.503-4%
Operating Margin---15.864-18.527+17%-6.107-62%-15.355-3%-15.355-3%
Operating Ratio--16.86419.375-13%7.187+135%23.156-27%23.156-27%
Pb Ratio2.964+63%1.0840.313+247%0.508+114%1.162-7%1.162-7%
Pe Ratio-1.927-173%-0.705-0.186-74%-0.471-33%-1.664+136%-1.664+136%
Price Per Share23.670+63%8.6602.664+225%0.886+877%5.841+48%5.841+48%
Price To Free Cash Flow Ratio-1.844-173%-0.675-0.205-70%-0.548-19%-2.072+207%-2.072+207%
Price To Total Gains Ratio-2.073-173%-0.758-0.097-87%-2.262+198%-3.005+296%-3.005+296%
Quick Ratio--5.4646.983-22%4.046+35%7.702-29%7.702-29%
Return On Assets---0.218-0.156-28%-0.181-17%-0.159-27%-0.159-27%
Return On Equity---0.384-0.299-22%-0.270-30%-0.199-48%-0.199-48%
Total Gains Per Share---11.4201.682-779%-0.396-97%0.465-2555%0.465-2555%
Usd Book Value--50096000.00067300250.000-26%78276500.000-36%91779000.000-45%91779000.000-45%
Usd Book Value Change Per Share---11.4201.682-779%-0.398-97%0.399-2960%0.399-2960%
Usd Book Value Per Share--7.98712.980-38%1.818+339%4.549+76%4.549+76%
Usd Dividend Per Share----0%0.003-100%0.066-100%0.066-100%
Usd Enterprise Value--90910040.06068939023.719+32%99020932.403-8%356636021.035-75%356636021.035-75%
Usd Eps---3.070-3.469+13%-0.474-85%-1.269-59%-1.269-59%
Usd Free Cash Flow---20127000.000-21276750.000+6%-18308000.000-9%-21520850.000+7%-21520850.000+7%
Usd Free Cash Flow Per Share---3.209-4.303+34%-0.425-87%-1.346-58%-1.346-58%
Usd Free Cash Flow To Equity Per Share---3.210-2.550-21%-0.422-87%-0.402-87%-0.402-87%
Usd Market Cap81997614.000+34%54318040.06016835023.719+223%38195182.403+42%202926966.828-73%202926966.828-73%
Usd Price Per Share23.670+63%8.6602.664+225%0.886+877%5.841+48%5.841+48%
Usd Profit---19259000.000-19238250.0000%-20418250.000+6%-24392150.000+27%-24392150.000+27%
Usd Revenue--1269000.0001499250.000-15%4096250.000-69%1429450.000-11%1429450.000-11%
Usd Total Gains Per Share---11.4201.682-779%-0.396-97%0.465-2555%0.465-2555%
 EOD+5 -3MRQTTM+18 -20YOY+13 -265Y+11 -2910Y+11 -29

3.3 Fundamental Score

Let's check the fundamental score of Aligos Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.927
Price to Book Ratio (EOD)Between0-12.964
Net Profit Margin (MRQ)Greater than0-15.177
Operating Margin (MRQ)Greater than0-15.864
Quick Ratio (MRQ)Greater than15.464
Current Ratio (MRQ)Greater than13.809
Debt to Asset Ratio (MRQ)Less than10.433
Debt to Equity Ratio (MRQ)Less than10.765
Return on Equity (MRQ)Greater than0.15-0.384
Return on Assets (MRQ)Greater than0.05-0.218
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Aligos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.623
Ma 20Greater thanMa 5026.780
Ma 50Greater thanMa 10031.936
Ma 100Greater thanMa 20021.911
OpenGreater thanClose21.130
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Aligos Therapeutics Inc

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2025-02-06 10:37:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aligos earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • A Net Profit Margin of -1,517.7% means that $-15.18 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aligos Therapeutics Inc:

  • The MRQ is -1,517.7%. The company is making a huge loss. -2
  • The TTM is -1,404.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,517.7%TTM-1,404.2%-113.4%
TTM-1,404.2%YOY-572.9%-831.3%
TTM-1,404.2%5Y-1,450.3%+46.1%
5Y-1,450.3%10Y-1,450.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,517.7%-100.3%-1,417.4%
TTM-1,404.2%-211.5%-1,192.7%
YOY-572.9%-213.8%-359.1%
5Y-1,450.3%-346.2%-1,104.1%
10Y-1,450.3%-489.2%-961.1%
4.3.1.2. Return on Assets

Shows how efficient Aligos is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • -21.8% Return on Assets means that Aligos generated $-0.22 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aligos Therapeutics Inc:

  • The MRQ is -21.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.8%TTM-15.6%-6.2%
TTM-15.6%YOY-18.1%+2.5%
TTM-15.6%5Y-15.9%+0.3%
5Y-15.9%10Y-15.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.8%-12.0%-9.8%
TTM-15.6%-12.1%-3.5%
YOY-18.1%-11.4%-6.7%
5Y-15.9%-12.8%-3.1%
10Y-15.9%-14.6%-1.3%
4.3.1.3. Return on Equity

Shows how efficient Aligos is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • -38.4% Return on Equity means Aligos generated $-0.38 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aligos Therapeutics Inc:

  • The MRQ is -38.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -29.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-38.4%TTM-29.9%-8.6%
TTM-29.9%YOY-27.0%-2.9%
TTM-29.9%5Y-19.9%-10.0%
5Y-19.9%10Y-19.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38.4%-15.4%-23.0%
TTM-29.9%-16.2%-13.7%
YOY-27.0%-14.7%-12.3%
5Y-19.9%-18.6%-1.3%
10Y-19.9%-19.5%-0.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aligos Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aligos is operating .

  • Measures how much profit Aligos makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • An Operating Margin of -1,586.4% means the company generated $-15.86  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aligos Therapeutics Inc:

  • The MRQ is -1,586.4%. The company is operating very inefficient. -2
  • The TTM is -1,852.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,586.4%TTM-1,852.7%+266.3%
TTM-1,852.7%YOY-610.7%-1,242.0%
TTM-1,852.7%5Y-1,535.5%-317.2%
5Y-1,535.5%10Y-1,535.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,586.4%-201.5%-1,384.9%
TTM-1,852.7%-313.4%-1,539.3%
YOY-610.7%-215.2%-395.5%
5Y-1,535.5%-371.8%-1,163.7%
10Y-1,535.5%-492.1%-1,043.4%
4.3.2.2. Operating Ratio

Measures how efficient Aligos is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 16.86 means that the operating costs are $16.86 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aligos Therapeutics Inc:

  • The MRQ is 16.864. The company is inefficient in keeping operating costs low. -1
  • The TTM is 19.375. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ16.864TTM19.375-2.511
TTM19.375YOY7.187+12.187
TTM19.3755Y23.156-3.782
5Y23.15610Y23.1560.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.8642.139+14.725
TTM19.3753.198+16.177
YOY7.1873.358+3.829
5Y23.1564.842+18.314
10Y23.1566.500+16.656
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aligos Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aligos is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.81 means the company has $3.81 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aligos Therapeutics Inc:

  • The MRQ is 3.809. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.047. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.809TTM5.047-1.238
TTM5.047YOY3.678+1.369
TTM5.0475Y5.719-0.672
5Y5.71910Y5.7190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8093.610+0.199
TTM5.0473.871+1.176
YOY3.6784.609-0.931
5Y5.7195.977-0.258
10Y5.7196.216-0.497
4.4.3.2. Quick Ratio

Measures if Aligos is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • A Quick Ratio of 5.46 means the company can pay off $5.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aligos Therapeutics Inc:

  • The MRQ is 5.464. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.983. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.464TTM6.983-1.519
TTM6.983YOY4.046+2.937
TTM6.9835Y7.702-0.719
5Y7.70210Y7.7020.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4643.085+2.379
TTM6.9833.360+3.623
YOY4.0464.400-0.354
5Y7.7025.972+1.730
10Y7.7026.483+1.219
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aligos Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aligos assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aligos to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.43 means that Aligos assets are financed with 43.3% credit (debt) and the remaining percentage (100% - 43.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aligos Therapeutics Inc:

  • The MRQ is 0.433. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.437. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.433TTM0.437-0.004
TTM0.437YOY0.325+0.112
TTM0.4375Y0.515-0.078
5Y0.51510Y0.5150.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4330.341+0.092
TTM0.4370.343+0.094
YOY0.3250.315+0.010
5Y0.5150.363+0.152
10Y0.5150.384+0.131
4.5.4.2. Debt to Equity Ratio

Measures if Aligos is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • A Debt to Equity ratio of 76.5% means that company has $0.77 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aligos Therapeutics Inc:

  • The MRQ is 0.765. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.799. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.765TTM0.799-0.033
TTM0.799YOY0.485+0.314
TTM0.7995Y0.468+0.331
5Y0.46810Y0.4680.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7650.386+0.379
TTM0.7990.429+0.370
YOY0.4850.391+0.094
5Y0.4680.450+0.018
10Y0.4680.495-0.027
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aligos generates.

  • Above 15 is considered overpriced but always compare Aligos to the Biotechnology industry mean.
  • A PE ratio of -0.71 means the investor is paying $-0.71 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aligos Therapeutics Inc:

  • The EOD is -1.927. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.705. Based on the earnings, the company is expensive. -2
  • The TTM is -0.186. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.927MRQ-0.705-1.222
MRQ-0.705TTM-0.186-0.519
TTM-0.186YOY-0.471+0.285
TTM-0.1865Y-1.664+1.478
5Y-1.66410Y-1.6640.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.927-2.247+0.320
MRQ-0.705-2.706+2.001
TTM-0.186-3.253+3.067
YOY-0.471-3.392+2.921
5Y-1.664-6.132+4.468
10Y-1.664-6.735+5.071
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aligos Therapeutics Inc:

  • The EOD is -1.844. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.675. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.205. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.844MRQ-0.675-1.169
MRQ-0.675TTM-0.205-0.470
TTM-0.205YOY-0.548+0.343
TTM-0.2055Y-2.072+1.867
5Y-2.07210Y-2.0720.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.844-3.026+1.182
MRQ-0.675-3.582+2.907
TTM-0.205-3.816+3.611
YOY-0.548-4.463+3.915
5Y-2.072-8.265+6.193
10Y-2.072-9.266+7.194
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aligos is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.08 means the investor is paying $1.08 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aligos Therapeutics Inc:

  • The EOD is 2.964. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.084. Based on the equity, the company is underpriced. +1
  • The TTM is 0.313. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD2.964MRQ1.084+1.879
MRQ1.084TTM0.313+0.772
TTM0.313YOY0.508-0.195
TTM0.3135Y1.162-0.850
5Y1.16210Y1.1620.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.9641.948+1.016
MRQ1.0842.223-1.139
TTM0.3132.427-2.114
YOY0.5082.469-1.961
5Y1.1623.767-2.605
10Y1.1624.507-3.345
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aligos Therapeutics Inc.

4.8.1. Institutions holding Aligos Therapeutics Inc

Institutions are holding 49.644% of the shares of Aligos Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Armistice Capital, LLC8.78220.0436315095248398.5576
2024-09-30EcoR1 Capital, LLC7.12320.0758255573-6-0.0023
2024-09-30Deep Track Capital, LP6.80370.0671244110-1-0.0004
2024-09-30Adage Capital Partners Gp LLC6.09870.0034218813188139.4065
2024-09-30Vivo Capital, LLC3.95440.1017141879-2-0.0014
2024-09-30Woodline Partners LP2.56340.00679197170723332.8454
2024-09-30Baker Bros Advisors LP2.31490.007583055-1-0.0012
2024-09-30Hillhouse Capital Advisors, Ltd.2.12510.014576247-48621-38.9379
2024-09-30UBS O'Connor LLC1.87010.0448670962709667.74
2024-09-30Vanguard Group Inc1.778606381400
2024-09-30SILVERARC CAPITAL MANAGEMENT, LLC0.73080.05126219-2-0.0076
2024-09-30Geode Capital Management, LLC0.6705024056782848.2376
2024-12-31DRIVE WEALTH MANAGEMENT, LLC0.6410.224623000230000
2024-09-30Renaissance Technologies Corp0.37470.000213443-17311-56.2886
2024-09-30Charles Schwab Investment Management Inc0.333901198010725854.5817
2024-09-30Qube Research & Technologies0.30510.000110947109470
2024-09-30BlackRock Inc0.252709067-29-0.3188
2024-09-30Bank of America Corp0.190906851-25790-79.0111
2024-12-31Golden State Wealth Management, LLC0.07450.01626742000296.7359
2024-09-30CWM, LLC duplicate0.01880675-1-0.1479
Total 47.00720.6571686565+104207+6.2%

4.9.2. Funds holding Aligos Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31Vanguard Total Stock Mkt Idx Inv1.84170.0002660791328425.1615
2024-12-31Vanguard Institutional Extnd Mkt Idx Tr0.82530.00112961000
2024-12-31Fidelity Extended Market Index0.39320.001414108179914.6153
2025-01-30Schwab US Small-Cap ETFℱ0.31860.00151143100
2024-12-31Extended Equity Market Fund K0.14810.001453124171365.5565
2024-12-31Fidelity Total Market Index0.12150.0002436100
2024-06-30SSgA U.S. Total Market Index Strategy0.003803404101042.1888
2024-12-31Fidelity Series Total Market Index0.09070.0002325631810.8237
2024-12-31Northern Trust Extended Eq Market Idx0.08010.00142873142798.686
2024-12-31NT Ext Equity Mkt Idx Fd - L0.08010.00142873142798.686
2024-12-31NT Ext Equity Mkt Idx Fd - NL0.05990.0013215000
2024-12-31Spartan Extended Market Index Pool E0.05860.00142101984.8927
2024-12-31Fidelity Nasdaq Composite Index0.05240.000418791528435.3276
2024-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.04750.00131704-28-1.6166
2025-01-30Schwab US Broad Market ETFℱ0.04460.0001160000
2024-12-31Spartan Total Market Index Pool E0.04290.000215391082236.7615
2024-12-31Schwab Total Stock Market Index0.0350.0002125500
2024-11-30DFA US Targeted Value I0.03150.0002113100
2024-12-31Vanguard Balanced Index Inv0.02990.0001107310730
2025-01-30Avantis US Small Cap Equity ETF0.02410.0014864252.9797
Total 4.32950.0154158603+27214+17.2%

5.3. Insider Transactions

Insiders are holding 17.799% of the shares of Aligos Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-10-25Carole NuechterleinBUY31734419
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets88,426
Total Liabilities38,330
Total Stockholder Equity50,096
 As reported
Total Liabilities 38,330
Total Stockholder Equity+ 50,096
Total Assets = 88,426

Assets

Total Assets88,426
Total Current Assets79,822
Long-term Assets8,604
Total Current Assets
Cash And Cash Equivalents 35,331
Short-term Investments 39,591
Other Current Assets 4,900
Total Current Assets  (as reported)79,822
Total Current Assets  (calculated)79,822
+/-0
Long-term Assets
Property Plant Equipment 7,969
Long-term Assets Other 635
Long-term Assets  (as reported)8,604
Long-term Assets  (calculated)8,604
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities20,956
Long-term Liabilities17,374
Total Stockholder Equity50,096
Total Current Liabilities
Short-term Debt 10,407
Accounts payable 2,740
Other Current Liabilities 14,161
Total Current Liabilities  (as reported)20,956
Total Current Liabilities  (calculated)27,308
+/- 6,352
Long-term Liabilities
Capital Lease Obligations 9,133
Long-term Liabilities Other 46
Long-term Liabilities  (as reported)17,374
Long-term Liabilities  (calculated)9,179
+/- 8,195
Total Stockholder Equity
Common Stock8
Retained Earnings -535,858
Accumulated Other Comprehensive Income 577
Other Stockholders Equity 585,369
Total Stockholder Equity (as reported)50,096
Total Stockholder Equity (calculated)50,096
+/-0
Other
Capital Stock8
Cash and Short Term Investments 74,922
Common Stock Shares Outstanding 6,272
Current Deferred Revenue655
Liabilities and Stockholders Equity 88,426
Net Debt -26,198
Net Invested Capital 50,096
Net Working Capital 58,866
Property Plant and Equipment Gross 19,510
Short Long Term Debt Total 9,133



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-06-302018-03-312017-12-31
> Total Assets 
0
0
0
0
0
0
0
146,520
0
148,676
92,183
265,302
234,540
211,876
263,068
235,369
210,470
182,523
164,069
146,693
121,738
106,130
85,852
153,903
127,902
108,811
88,426
88,426108,811127,902153,90385,852106,130121,738146,693164,069182,523210,470235,369263,068211,876234,540265,30292,183148,6760146,5200000000
   > Total Current Assets 
0
0
0
0
90,852
0
0
120,226
117,663
132,229
73,693
250,017
219,826
196,642
248,670
204,424
195,076
167,685
150,093
133,545
109,429
94,243
74,643
141,084
118,064
99,570
79,822
79,82299,570118,064141,08474,64394,243109,429133,545150,093167,685195,076204,424248,670196,642219,826250,01773,693132,229117,663120,2260090,8520000
       Cash And Cash Equivalents 
0
0
0
0
-90,852
0
0
69,565
-117,663
63,453
31,816
220,383
200,362
187,650
239,734
186,816
104,562
71,172
86,440
81,347
78,671
90,828
70,429
135,774
24,367
45,148
35,331
35,33145,14824,367135,77470,42990,82878,67181,34786,44071,172104,562186,816239,734187,650200,362220,38331,81663,453-117,66369,56500-90,8520000
       Short-term Investments 
0
0
0
0
181,704
0
0
48,098
235,326
65,444
38,248
23,130
13,053
3,003
2,451
3,918
78,660
88,172
55,864
44,480
24,845
10
0
0
88,588
49,458
39,591
39,59149,45888,588001024,84544,48055,86488,17278,6603,9182,4513,00313,05323,13038,24865,444235,32648,09800181,7040000
       Other Current Assets 
0
0
0
0
0
0
0
2,025
3,332
2,779
3,073
5,944
5,855
5,796
5,832
13,690
10,295
8,320
7,709
7,718
5,913
3,363
4,140
5,310
5,109
4,964
4,900
4,9004,9645,1095,3104,1403,3635,9137,7187,7098,32010,29513,6905,8325,7965,8555,9443,0732,7793,3322,0250000000
   > Long-term Assets 
0
0
0
0
0
0
0
26,294
0
16,447
18,490
15,285
14,714
15,234
14,398
30,945
15,394
14,838
13,976
13,148
12,309
11,887
11,209
12,819
9,838
9,241
8,604
8,6049,2419,83812,81911,20911,88712,30913,14813,97614,83815,39430,94514,39815,23414,71415,28518,49016,447026,2940000000
       Property Plant Equipment 
0
0
0
0
0
0
0
16,087
16,212
16,212
15,646
14,908
14,526
13,753
13,158
14,969
14,778
14,222
13,323
12,514
11,677
11,263
10,586
9,818
9,213
8,610
7,969
7,9698,6109,2139,81810,58611,26311,67712,51413,32314,22214,77814,96913,15813,75314,52614,90815,64616,21216,21216,0870000000
       Long Term Investments 
0
0
0
0
0
0
0
10,019
0
0
0
0
0
0
492
15,110
0
0
0
0
0
0
0
0
0
0
0
0000000000015,11049200000010,0190000000
       Other Assets 
0
0
0
0
0
0
0
0
235
235
2,844
7
188
1,481
13,906
866
616
616
653
634
0
624
0
0
0
0
0
00000624063465361661686613,9061,48118872,84423523500000000
> Total Liabilities 
0
0
0
0
0
0
0
211,411
0
26,718
228,851
45,263
39,320
42,992
46,057
50,638
57,584
45,542
42,056
42,793
36,988
36,495
31,031
61,823
68,106
41,582
38,330
38,33041,58268,10661,82331,03136,49536,98842,79342,05645,54257,58450,63846,05742,99239,32045,263228,85126,7180211,4110000000
   > Total Current Liabilities 
0
0
0
0
0
0
0
13,818
15,364
15,364
19,984
30,274
25,231
30,098
34,780
38,957
41,356
31,653
30,541
33,129
28,079
27,225
22,468
23,906
18,880
23,564
20,956
20,95623,56418,88023,90622,46827,22528,07933,12930,54131,65341,35638,95734,78030,09825,23130,27419,98415,36415,36413,8180000000
       Short-term Debt 
0
0
0
0
0
0
0
2,452
0
2,456
2,520
2,506
2,557
2,633
2,782
2,907
3,295
2,934
3,207
3,143
3,149
3,237
3,255
3,239
3,274
3,355
10,407
10,4073,3553,2743,2393,2553,2373,1493,1433,2072,9343,2952,9072,7822,6332,5572,5062,5202,45602,4520000000
       Accounts payable 
0
0
0
0
0
0
0
3,767
3,296
3,296
7,682
3,313
2,810
1,593
2,601
3,015
3,755
2,762
2,931
4,737
2,822
3,241
2,941
2,517
2,842
6,819
2,740
2,7406,8192,8422,5172,9413,2412,8224,7372,9312,7623,7553,0152,6011,5932,8103,3137,6823,2963,2963,7670000000
       Other Current Liabilities 
0
0
0
0
0
0
0
753
0
806
650
16,564
12,283
19,060
22,760
25,394
19,239
12,824
13,678
16,039
15,081
13,795
12,322
16,842
12,043
12,064
14,161
14,16112,06412,04316,84212,32213,79515,08116,03913,67812,82419,23925,39422,76019,06012,28316,56465080607530000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
197,593
0
11,354
208,867
14,989
14,089
12,894
11,277
11,681
16,228
13,889
11,515
9,664
8,909
9,270
8,563
37,917
49,226
18,018
17,374
17,37418,01849,22637,9178,5639,2708,9099,66411,51513,88916,22811,68111,27712,89414,08914,989208,86711,3540197,5930000000
       Other Liabilities 
0
0
0
0
0
0
0
0
3,289
3,289
15,475
4,488
3,776
3,000
11,277
133
5,146
3,386
1,689
233
0
93
0
0
0
0
0
000009302331,6893,3865,14613311,2773,0003,7764,48815,4753,2893,28900000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
2,610
0
0
737
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000737002,6100000000000
> Total Stockholder Equity
0
0
0
0
86,771
0
0
-64,891
117,188
121,958
-136,668
220,039
195,220
168,884
217,011
184,731
152,886
136,981
122,013
103,900
84,750
69,635
54,821
92,080
59,796
67,229
50,096
50,09667,22959,79692,08054,82169,63584,750103,900122,013136,981152,886184,731217,011168,884195,220220,039-136,668121,958117,188-64,8910086,7710000
   Common Stock
0
0
0
0
0
0
0
0
4
2
0
4
4
4
4
4
4
4
4
4
4
4
4
7
7
8
8
887744444444444402400000000
   Retained Earnings Total Equity000000-422,073-399,118000-303,072-265,358-232,232-202,414-174,74000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
-115
0
150
32
-188
-227
-251
-250
452
204
50
159
401
499
497
497
545
476
494
577
57749447654549749749940115950204452-250-251-227-188321500-1150000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
394,963
397,857
401,363
482,615
487,347
0
0
0
502,613
506,320
0
0
0
0
0
0
000000506,320502,613000487,347482,615401,363397,857394,96300000000000
   Treasury Stock000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
-13,748
0
0
-180,658
-64,891
46,263
-178,946
129,661
163,317
189,487
482,615
487,347
491,365
495,538
499,082
502,613
506,320
509,998
513,225
578,325
580,973
583,326
585,369
585,369583,326580,973578,325513,225509,998506,320502,613499,082495,538491,365487,347482,615189,487163,317129,661-178,94646,263-64,891-180,65800-13,7480000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue15,529
Cost of Revenue-3,069
Gross Profit12,46012,460
 
Operating Income (+$)
Gross Profit12,460
Operating Expense-103,656
Operating Income-88,127-91,196
 
Operating Expense (+$)
Research Development73,040
Selling General Administrative30,616
Selling And Marketing Expenses3,769
Operating Expense103,656107,425
 
Net Interest Income (+$)
Interest Income1,243
Interest Expense-0
Other Finance Cost-0
Net Interest Income1,243
 
Pretax Income (+$)
Operating Income-88,127
Net Interest Income1,243
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-86,884-89,370
EBIT - interestExpense = -88,127
-86,884
-87,679
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-88,127-86,884
Earnings Before Interest and Taxes (EBITDA)-85,058
 
After tax Income (+$)
Income Before Tax-86,884
Tax Provision-795
Net Income From Continuing Ops-87,679-87,679
Net Income-87,679
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses102,956
Total Other Income/Expenses Net1,243-1,243
 

Technical Analysis of Aligos
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aligos. The general trend of Aligos is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aligos's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aligos Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 21.65 < 28.10 < 34.53.

The bearish price targets are: 10.39 > 6.76.

Tweet this
Aligos Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aligos Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aligos Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aligos Therapeutics Inc. The current macd is -2.40974592.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aligos price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aligos. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aligos price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Aligos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAligos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aligos Therapeutics Inc. The current adx is 31.57.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aligos shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Aligos Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aligos Therapeutics Inc. The current sar is 30.20.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aligos Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aligos Therapeutics Inc. The current rsi is 41.62. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Aligos Therapeutics Inc Daily Relative Strength Index (RSI) ChartAligos Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aligos Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aligos price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Aligos Therapeutics Inc Daily Stochastic Oscillator ChartAligos Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aligos Therapeutics Inc. The current cci is -92.79314152.

Aligos Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAligos Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aligos Therapeutics Inc. The current cmo is -17.14152108.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aligos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAligos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aligos Therapeutics Inc. The current willr is -62.31422505.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Aligos is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Aligos Therapeutics Inc Daily Williams %R ChartAligos Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aligos Therapeutics Inc. The current atr is 3.37644785.

Aligos Therapeutics Inc Daily Average True Range (ATR) ChartAligos Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aligos Therapeutics Inc. The current obv is 6,102,879.

Aligos Therapeutics Inc Daily On-Balance Volume (OBV) ChartAligos Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aligos Therapeutics Inc. The current mfi is 49.76.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Aligos Therapeutics Inc Daily Money Flow Index (MFI) ChartAligos Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aligos Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-09-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-31MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-06STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-08MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-19STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-10STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Aligos Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aligos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.623
Ma 20Greater thanMa 5026.780
Ma 50Greater thanMa 10031.936
Ma 100Greater thanMa 20021.911
OpenGreater thanClose21.130
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aligos with someone you think should read this too:
  • Are you bullish or bearish on Aligos? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aligos? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aligos Therapeutics Inc

I send you an email if I find something interesting about Aligos Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aligos Therapeutics Inc.

Receive notifications about Aligos Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.